Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
California 62 Florida 56 Texas 31 Georgia 30 Arizona 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca105 Eli Lilly and Company89 Merck Sharp & Dohme LLC72 AbbVie68 Janssen Research & Development, LLC67 Clear sponsor filter
State
California62 Florida56 Texas31 Georgia30 Arizona30
All 45 states
Target enrolment
to

Trials with a site in Georgia

30 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
NCT07805707Influenza, Human
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Recruiting
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
NCT07628049Respiratory Syncytial Virus Infections+Metapneumovirus
GlaxoSmithKline
Phase 1/2
1,456
Georgia, Kansas, Washington
2026-06-05
Recruiting
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
NCT07406360Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
GlaxoSmithKline
Phase 3
1,209
Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina
2026-05-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311Multiple Myeloma
DrugsBelantamab mafodotin·Velcade·Carfilzomib·Pomalidomide
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395Irritable Bowel Syndrome
DrugCamlipixant
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
NCT07464314Influenza, Human+COVID-19
GlaxoSmithKline
Phase 1
225
Alabama, Arkansas, California, Florida, Georgia, Texas, Virginia, Washington
2026-03-09
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
1,196
California, Colorado, Florida, Georgia, Idaho, Kentucky, Louisiana, Maine
2025-10-20
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
961
Alabama, Colorado, Florida, Georgia, Idaho, Illinois, Louisiana, Maine
2025-06-23
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06740630Chickenpox
DrugsHepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13·PCV 20
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Maine
2024-12-16
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
DrugGSK4532990
GlaxoSmithKline
Phase 2
393
Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2024-09-27
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
DrugRSVPreF3 OA vaccine
GlaxoSmithKline
Phase 3
10,212
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-08-01
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-03-21
Active, closed
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386Asthma
DrugMepolizumab
GlaxoSmithKline
Phase 4
336
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana, Maryland
2024-03-20
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
DrugGSK3862995B
GlaxoSmithKline
Phase 1
127
Arizona, Florida, Georgia, North Carolina, Oregon, Pennsylvania, South Carolina, Texas
2023-11-27
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-08-01
Recruiting
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102Asthma
DrugFF/UMEC/VI
GlaxoSmithKline
Phase 3
138
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-04-24
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2023-01-02
Recruiting
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368Hypereosinophilic Syndrome
DrugDepemokimab
GlaxoSmithKline
Phase 3
109
California, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio, South Carolina
2022-09-06
Active, closed
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
NCT05087056Meningitis, Meningococcal
GlaxoSmithKline
Phase 2
305
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Indiana, Kentucky
2021-11-18
Active, closed
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
NCT07217184Multiple Myeloma
DrugsBelantamab mafodotin·Isatuximab
GlaxoSmithKline
Phase 1/2
30
Georgia, Massachusetts, Michigan, Wisconsin
2021-07-29
Recruiting
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247Ovarian Neoplasms, Breast Neoplasms
DrugNiraparib
GlaxoSmithKline
Phase 2
37
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, New Jersey
2021-04-16
Active, closed
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
NCT07084896Multiple Myeloma
DrugsNirogacestat·Belantamab mafodotin
GlaxoSmithKline
Phase 1/2
106
Georgia, Massachusetts, Michigan, Wisconsin
2020-06-08
Active, closed
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
NCT07217119Multiple Myeloma
DrugsFeladilimab·Belantamab mafodotin
GlaxoSmithKline
Phase 1/2
25
Georgia, Wisconsin
2019-11-26
Active, closed
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04126200Multiple Myeloma
DrugsFeladilimab·Nirogacestat·Belantamab mafodotin·Isatuximab
GlaxoSmithKline
Phase 1/2
208
Georgia, Indiana, Massachusetts, Michigan, Wisconsin
2019-10-07
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Arizona, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Minnesota
2018-05-03
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Georgia that also match the filters currently applied.

How many clinical trials are recruiting in Georgia?

19 of the 30 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Georgia), 30 studies
PhaseStudiesRecruitingShare
Phase 3131243.3%
Phase 28526.7%
Phase 1/25116.7%
Phase 1216.7%
Phase 4206.7%

Most active sponsors

Lead sponsors with the most studies (Georgia)
Lead sponsorStudiesRecruiting
GlaxoSmithKline3019
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.